Drug combinations to treat multiple myeloma
This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.
1. A method for treating a subject with multiple myeloma, comprising administering to the subject a combination therapy which comprises an effective amount of the proteasome inhibitor bortezomib and Compound 1:
as the L-malate salt, wherein Compound 1 as the L-malate salt is administered once daily as a pharmaceutical formulation as provided in one of the following tables
Ingredient
(% w/w)
Compound 1
31.68
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
3.00
Total Intra-granular
95.95
Silicon dioxide, Colloidal
0.30
Croscarmellose Sodium
3.00
Magnesium Stearate
0.75
Total
100.00
Ingredient
(% w/w)
Compound 1, L-malate salt
31.68
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
6.00
Silicon dioxide, Colloidal
0.30
Magnesium Stearate
0.75
Total
100.00.
2. A method of reducing mean and total area of osteolytic bone lesions in multiple myeloma human patients comprising administering to the patient an effective amount of the proteasome inhibitor bortezomib and Compound 1:
as the L-malate salt, wherein Compound 1 as the L-malate salt is administered once daily as a pharmaceutical formulation as provided in one of the following tables
Ingredient
(% w/w)
Compound 1
31.68
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
3.00
Total Intra-granular
95.95
Silicon dioxide, Colloidal
0.30
Croscarmellose Sodium
3.00
Magnesium Stearate
0.75
Total
100.00
Ingredient
(% w/w)
Compound 1, L-malate salt
31.68
Microcrystalline Cellulose
38.85
Lactose anhydrous
19.42
Hydroxypropyl Cellulose
3.00
Croscarmellose Sodium
6.00
Silicon dioxide, Colloidal
0.30
Magnesium Stearate
0.75
Total
100.00.
3. The method of claim 1 , wherein the subject is human.
4. The method of claim 1 , wherein the subject has bone lesions.